

**Amendments to the Claims:**

Please amend claims 57 and 59 as set forth below.

Please cancel claim 74 without prejudice.

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of the Claims**

Claims 1-56 (Canceled)

57. (Currently Amended) A substantially purified peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 18, 20 to 25 and 26.

58. (Previously Presented) A chimeric polypeptide, comprising a peptide according to claim 57 linked to at least one heterologous polypeptide.

59. (Currently Amended) A composition, comprising at least one peptide of claim 57 and a pharmaceutically acceptable carrier.

Claims 60-61 (Canceled)

62. (Original) The composition of claim 59, further comprising an immunoadjuvant.

63. (Original) The composition of claim 62, wherein the immunoadjuvant is a cytokine.

64. (Original) The composition of claim 63, wherein the cytokine induces pro-inflammatory activity.

65. (Original) The composition of claim 63, wherein the cytokine induces anti-inflammatory activity.

66. (Original) The composition of claim 62, wherein the immunoadjuvant is selected from the group consisting of Freund's complete adjuvant, Freund's incomplete adjuvant, and alum.

In re Application of:  
Albani et al.  
Application No.: 10/001,938  
Filed: October 31, 2001  
Page 5

PATENT  
Attorney Docket No.: UCSD1360-1

Claims 67-73 (Canceled)

74. (Canceled)